

Title (en)

COMBINED THERAPEUTICAL TREATMENT OF HYPERPROLIFERATIVE DISEASES

Title (de)

KOMBINIERTES THERAPEUTISCHES VERFAHREN ZUR BEHANDLUNG VON HYPERPROLIFERATIVEN KRANKHEITEN

Title (fr)

TRAITEMENT THERAPEUTIQUE COMBINE DES PATHOLOGIES HYPERPROLIFERATIVES

Publication

**EP 0800399 B1 20020814 (FR)**

Application

**EP 96901387 A 19960112**

Priority

- FR 9600056 W 19960112
- FR 9500436 A 19950117

Abstract (en)

[origin: WO9622101A1] A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.

IPC 1-7

**A61K 31/70**; **A61K 33/24**; **A61K 31/7105**; **A61K 31/711**; **A61P 35/00**

IPC 8 full level

**A61K 31/335** (2006.01); **A61K 31/435** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7105** (2006.01); **A61K 31/711** (2006.01); **A61K 38/00** (2006.01); **A61K 33/243** (2019.01); **A61K 35/76** (2006.01); **A61K 38/19** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR US)

**A61K 31/70** (2013.01 - EP KR US); **A61K 33/243** (2019.01 - EP KR US); **A61K 38/191** (2013.01 - EP KR US); **A61P 9/10** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP US)

1. **A61K 38/191** + **A61K 31/70**
2. **A61K 33/24** + **A61K 31/70**
3. **A61K 31/70** + **A61K 31/70**
4. **A61K 31/70** + **A61K 31/70**
5. **A61K 31/70** + **A61K 31/475**
6. **A61K 31/70** + **A61K 31/47**
7. **A61K 31/70** + **A61K 31/335**
8. **A61K 31/70** + **A61K 2300/00**
9. **A61K 33/24** + **A61K 2300/00**
10. **A61K 38/191** + **A61K 2300/00**

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

**WO 9622101 A1 19960725**; AT E222109 T1 20020815; AU 4542996 A 19960807; AU 716364 B2 20000224; BR 9606969 A 19971104; CA 2209771 A1 19960725; CA 2209771 C 20120103; CZ 226297 A3 19971015; CZ 298710 B6 20080102; DE 69622989 D1 20020919; DE 69622989 T2 20021205; DK 0800399 T3 20021202; EP 0800399 A1 19971015; EP 0800399 B1 20020814; ES 2180729 T3 20030216; FI 119911 B 20090515; FI 973023 A0 19970716; FI 973023 A 19970716; FR 2729295 A1 19960719; FR 2729295 B1 19970228; HU 229484 B1 20140128; HU P9802423 A2 19990201; HU P9802423 A3 20001128; JP 2008133291 A 20080612; JP 2012036201 A 20120223; JP 4580469 B2 20101110; JP 5031921 B2 20120926; JP H10512559 A 19981202; KR 100385266 B1 20050907; KR 19980701449 A 19980515; MX 9704490 A 19971031; NO 325418 B1 20080421; NO 973197 D0 19970709; NO 973197 L 19970709; PT 800399 E 20021231; SI 0800399 T1 20021231; SK 283989 B6 20040707; SK 95797 A3 19971210; US 2001021395 A1 20010913; US 2004127437 A1 20040701; US 2005209177 A9 20050922; US 6262032 B1 20010717; US 7884082 B2 20110208

DOCDB simple family (application)

**FR 9600056 W 19960112**; AT 96901387 T 19960112; AU 4542996 A 19960112; BR 9606969 A 19960112; CA 2209771 A 19960112; CZ 226297 A 19960112; DE 69622989 T 19960112; DK 96901387 T 19960112; EP 96901387 A 19960112; ES 96901387 T 19960112; FI 973023 A 19970716; FR 9500436 A 19950117; HU P9802423 A 19960112; JP 2008001848 A 20080109; JP 2011206858 A 20110922; JP 52207896 A 19960112; KR 19970704839 A 19970716; MX 9704490 A 19960112; NO 973197 A 19970709; PT 96901387 T 19960112; SI 9630511 T 19960112; SK 95797 A 19960112; US 41268403 A 20030414; US 81614401 A 20010326; US 87522297 A 19970717